Screener
ClearPoint Neuro CLPT Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by ClearPoint Neuro in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221890
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development costs | 4,522 | 3,379 |
| Sales and marketing expenses | 6,715 | 3,834 |
| General and administrative expenses | 4,997 | 4,082 |
| Operating loss | (8,478) | (6,163) |
| Other income (expense): | ||
| Other (expense) income, net | (35) | 4 |
| Interest income | 351 | 151 |
| Interest expense | (1,382) | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is ClearPoint Neuro's operating income?
- ClearPoint Neuro (CLPT) reported operating income of -$8.48M in Q1 2026.
- How has ClearPoint Neuro's operating income changed year-over-year?
- ClearPoint Neuro's operating income decreased by 37.6% year-over-year, from -$6.16M to -$8.48M.
- What is the long-term trend for ClearPoint Neuro's operating income?
- Over 4 years (2021 to 2025), ClearPoint Neuro's operating income has grown at a 15.9% compound annual growth rate (CAGR), from -$13.37M to -$24.16M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about ClearPoint Neuro's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude